New Agent for Leukemia Therapy : STI 571
Keywords:
-Abstract
-
Downloads
References
Verweij J, Judson I, van Oosterom A. STI 571: a magic bullet? European J Cancer 2001;37:1816-9.
Goldman JM, Melo JV. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1084-6.
Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
Cohen MH, Martin A, Pazdur R. FDA Report: Recently Approved Pharmaceutical Agents. ASCO News 2001:20-2.
Schiffer CA. STI-571: Current status and future prospects. Curr Opin Invest Drug 2001;2:1279-81.
Kalidas M, Kantarjian H, Talpaz M. Chronic myelogenous leukemia. JAMA 2001;286:895-8
.Joensuu H, Dimitrievic S. Tyrosine kinase inhibitor imatinib (ST1571) as an anticancer agent for solid tumours. ANN Med 2001;33:451-5.
Glivec (imatinib mesylate) International Package Leaflet. 2001:1-12.
Fang G, Kim CN, Perkins CL, et al. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood 2000;96:2246-52.
Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ. Efficacy of STI 571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cells. Blood 2000;96:3195-9.
Hehlmann R. Trial of IFN or STI571 before proceeding to allografting for CML? Leukemia 2000:14:1560-2.
Massumoto C, Hamerschlack N, Ferreira E, et al. Stem cell transplantation (PBSCT) for chronic myelogenous
leukemia (CML). Abstract of the 43" Annual Meeting of the American Society of Hematology 2001:4781a.
Lie AKW, Au WY, Ma SK, et al. Tyrosine kinase inhibitor ST1571 in treating Philadelphia chromosome positive (Ph+) leukemia relapsing from myelcablative allogeneic bone marrow transplantation (BMT): an early experience. Abstract of the 43" Annual Meeting of the American Society of Hematology 2001:47777a.
Visani G, Isidori A, Malagola M, et al. Efficacy of Glivec (ST1571) in conjunction with alpha-interferon in a case of relapsed P-190BCR-ABL-Positive acute Iymphoblastic leukemia. Abstract of the 43rd Annual Meeting of the American Society of Hematology 2001:2462a.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
